TScan Therapeutics, Inc. (NASDAQ:TCRX) Receives $7.80 Average PT from Brokerages

Shares of TScan Therapeutics, Inc. (NASDAQ:TCRX - Get Free Report) have been given a consensus recommendation of "Buy" by the five research firms that are presently covering the firm, MarketBeat Ratings reports. Five research analysts have rated the stock with a buy rating. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $7.80.

Several equities research analysts recently issued reports on TCRX shares. HC Wainwright cut their price target on TScan Therapeutics from $15.00 to $10.00 and set a "buy" rating for the company in a research note on Wednesday, May 7th. Wall Street Zen cut TScan Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday, June 14th. Morgan Stanley reiterated an "overweight" rating and issued a $10.00 price target on shares of TScan Therapeutics in a research note on Friday, March 14th. Wedbush restated an "outperform" rating and set a $7.00 price objective on shares of TScan Therapeutics in a research report on Tuesday, May 6th. Finally, Needham & Company LLC restated a "buy" rating and set a $9.00 price objective on shares of TScan Therapeutics in a research report on Tuesday, April 8th.

TScan Therapeutics Stock Up 0.2%

Shares of NASDAQ:TCRX traded up $0.00 during midday trading on Wednesday, reaching $1.84. The company had a trading volume of 99,701 shares, compared to its average volume of 510,301. The company has a quick ratio of 8.55, a current ratio of 8.55 and a debt-to-equity ratio of 0.15. The business's 50 day moving average price is $1.49 and its 200 day moving average price is $1.85. The stock has a market cap of $104.35 million, a PE ratio of -1.69 and a beta of 0.97. TScan Therapeutics has a 1-year low of $1.02 and a 1-year high of $7.89.

TScan Therapeutics (NASDAQ:TCRX - Get Free Report) last announced its quarterly earnings results on Monday, May 12th. The company reported ($0.26) earnings per share for the quarter, topping analysts' consensus estimates of ($0.28) by $0.02. The firm had revenue of $2.17 million for the quarter, compared to the consensus estimate of $1.62 million. TScan Therapeutics had a negative return on equity of 55.76% and a negative net margin of 2,974.08%. Research analysts forecast that TScan Therapeutics will post -1.12 EPS for the current fiscal year.

Insider Buying and Selling at TScan Therapeutics

In related news, major shareholder Lynx1 Capital Management Lp bought 1,388,794 shares of the business's stock in a transaction that occurred on Monday, May 19th. The shares were bought at an average price of $1.20 per share, with a total value of $1,666,552.80. Following the completion of the transaction, the insider directly owned 6,746,141 shares in the company, valued at approximately $8,095,369.20. This represents a 25.92% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 4.35% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the stock. Goldman Sachs Group Inc. boosted its position in shares of TScan Therapeutics by 6.0% during the first quarter. Goldman Sachs Group Inc. now owns 170,349 shares of the company's stock valued at $235,000 after buying an additional 9,676 shares during the last quarter. Checkpoint Capital L.P. boosted its position in shares of TScan Therapeutics by 14.9% during the first quarter. Checkpoint Capital L.P. now owns 2,017,650 shares of the company's stock valued at $2,784,000 after buying an additional 261,663 shares during the last quarter. BVF Inc. IL boosted its position in shares of TScan Therapeutics by 63.6% during the first quarter. BVF Inc. IL now owns 4,889,474 shares of the company's stock valued at $6,747,000 after buying an additional 1,900,000 shares during the last quarter. Troluce Capital Advisors LLC boosted its position in shares of TScan Therapeutics by 58.3% during the first quarter. Troluce Capital Advisors LLC now owns 83,758 shares of the company's stock valued at $116,000 after buying an additional 30,844 shares during the last quarter. Finally, Hsbc Holdings PLC purchased a new position in shares of TScan Therapeutics during the first quarter valued at approximately $49,000. Hedge funds and other institutional investors own 82.83% of the company's stock.

About TScan Therapeutics

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.